Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Enanta Pharmaceuticals (ENTA) stocks

Learn how to easily invest in Enanta Pharmaceuticals stocks.

Enanta Pharmaceuticals is a biotechnology business based in the US. Enanta Pharmaceuticals stocks (ENTA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $71.5 – an increase of 10.45% over the previous week. Enanta Pharmaceuticals employs 155 staff and has a trailing 12-month revenue of around $91.6 million.

How to buy stocks in Enanta Pharmaceuticals

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ENTA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Enanta Pharmaceuticals stock price (NASDAQ:ENTA)

Use our graph to track the performance of ENTA stocks over time.

Enanta Pharmaceuticals shares at a glance

Information last updated 2022-06-25.
Latest market close$45.01
52-week range$37.59 - $102.00
50-day moving average $51.74
200-day moving average $65.73
Wall St. target price$66.63
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-5.52

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95–$6.95
$0 if conditions met, otherwise $100 a year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99–$9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
FREE TRADES
Wealthsimple
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Enanta Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Enanta Pharmaceuticals price performance over time

Historical closes compared with the close of $45.01 from 2022-06-24

1 week (2022-06-21) 11.69%
1 month (2022-05-27) 14.04%
3 months (2022-03-24) -33.58%
6 months (2021-12-28) -39.99%
1 year (2021-06-28) 0.07%
2 years (2020-06-26) -9.40%
3 years (2019-06-28) 84.38
5 years (2017-06-28) 21.48%

Is Enanta Pharmaceuticals under- or over-valued?

Valuing Enanta Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enanta Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Enanta Pharmaceuticals's EBITDA

Enanta Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14.8 million.

The EBITDA is a measure of a Enanta Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Enanta Pharmaceuticals financials

Revenue TTM $91.6 million
Gross profit TTM $97.1 million
Return on assets TTM -18.84%
Return on equity TTM -28.27%
Profit margin -122.68%
Book value $17.39
Market capitalisation $932.3 million

TTM: trailing 12 months

Enanta Pharmaceuticals share dividends

We're not expecting Enanta Pharmaceuticals to pay a dividend over the next 12 months.

Enanta Pharmaceuticals share price volatility

Over the last 12 months, Enanta Pharmaceuticals's shares have ranged in value from as little as $37.59 up to $102. A popular way to gauge a stock's volatility is its "beta".

ENTA.US volatility(beta: 0.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enanta Pharmaceuticals's is 0.6742. This would suggest that Enanta Pharmaceuticals's shares are less volatile than average (for this exchange).

Enanta Pharmaceuticals overview

Enanta Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts. .

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site